Pharma major Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved divalproex sodium extended-release (ER) tablets USP, 250 mg and 500 mgThe product will be manufactured at Lupin’s Nagpur facility in India.Divalproex sodium ER tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote extended release (ER) tablets, 250 mg and 500 mg, of AbbVie Inc indicated for acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features, monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures and prophylaxis of migraine headachesDivalproex sodium extended-release (ER) tablets USP had annual sales of approximately US$ 130 million in the US, according to IQVIA MAT July 2020.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!